79 related articles for article (PubMed ID: 25389712)
21. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
Phanthunane P; Whiteford H; Vos T; Bertram M
J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
[TBL] [Abstract][Full Text] [Related]
22. Associations of non-melanoma skin cancer and melanoma, extra-cutaneous cancers and smoking in adults: a US population-based study.
Silverberg JI; Ratner D
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1389-97. PubMed ID: 25491569
[TBL] [Abstract][Full Text] [Related]
23. Costs of psychosis in 2010: findings from the second Australian National Survey of Psychosis.
Neil AL; Carr VJ; Mihalopoulos C; Mackinnon A; Morgan VA
Aust N Z J Psychiatry; 2014 Feb; 48(2):169-82. PubMed ID: 24097844
[TBL] [Abstract][Full Text] [Related]
24. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.
Crott R; Ali F; Burdette-Radoux S
Value Health; 2004; 7(4):423-32. PubMed ID: 15449634
[TBL] [Abstract][Full Text] [Related]
25. Rising annual costs of dizziness presentations to U.S. emergency departments.
Saber Tehrani AS; Coughlan D; Hsieh YH; Mantokoudis G; Korley FK; Kerber KA; Frick KD; Newman-Toker DE
Acad Emerg Med; 2013 Jul; 20(7):689-96. PubMed ID: 23859582
[TBL] [Abstract][Full Text] [Related]
26. Supply-and-demand discrepancy in academic pigmented lesion clinics: a case for a new health care delivery model.
Vickery EL; Seidler EM; Jones TE; Veledar E; Chen SC
JAMA Dermatol; 2014 Nov; 150(11):1167-72. PubMed ID: 25028988
[TBL] [Abstract][Full Text] [Related]
27. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
28. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors.
Haenssle HA; Korpas B; Hansen-Hagge C; Buhl T; Kaune KM; Johnsen S; Rosenberger A; Schön MP; Emmert S
Arch Dermatol; 2010 Mar; 146(3):257-64. PubMed ID: 20231495
[TBL] [Abstract][Full Text] [Related]
29. Long-term survival and cost analysis of an annual Barrett's surveillance programme.
Roberts KJ; Harper E; Alderson D; Hallissey M
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):399-403. PubMed ID: 19858726
[TBL] [Abstract][Full Text] [Related]
30. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada.
Amin M; Fergusson D; Wilson K; Tinmouth A; Aziz A; Coyle D; Hébert P
Transfusion; 2004 Oct; 44(10):1479-86. PubMed ID: 15383022
[TBL] [Abstract][Full Text] [Related]
31. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas.
Chen T; Fallah M; Försti A; Kharazmi E; Sundquist K; Hemminki K
JAMA Dermatol; 2015 Jun; 151(6):607-15. PubMed ID: 25671687
[TBL] [Abstract][Full Text] [Related]
32. Patterns of service utilisation within Australian hepatology clinics: high prevalence of advanced liver disease.
El-Atem NA; Wojcik K; Horsfall L; Irvine KM; Johnson T; McPhail SM; Powell EE
Intern Med J; 2016 Apr; 46(4):420-6. PubMed ID: 26762655
[TBL] [Abstract][Full Text] [Related]
33. A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting.
Eloubeidi MA; Homan RK; Martz MD; Theobald KE; Provenzale D
Am J Gastroenterol; 1999 Aug; 94(8):2033-6. PubMed ID: 10445524
[TBL] [Abstract][Full Text] [Related]
34. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
35. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
36. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of asthma clinic approach in the management of chronic asthma in Australia.
Mogasale V; Vos T
Aust N Z J Public Health; 2013 Jun; 37(3):205-10. PubMed ID: 23731101
[TBL] [Abstract][Full Text] [Related]
38. Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis.
Serra-Arbeloa P; Rabines-Juárez ÁO; Álvarez-Ruiz MS; Guillén-Grima F
Actas Dermosifiliogr; 2017 Apr; 108(3):229-236. PubMed ID: 27887672
[TBL] [Abstract][Full Text] [Related]
39. Implementing systematic melanoma risk assessment and risk-tailored surveillance in a skin cancer focussed dermatology clinic: A qualitative study of feasibility and acceptability to patients and clinic staff.
Smith AL; Smit AK; Laginha BI; Singh N; Gallo B; Martin L; Cust AE
Cancer Med; 2024 Jan; 13(2):e6976. PubMed ID: 38379327
[TBL] [Abstract][Full Text] [Related]
40. Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance.
Williams JTW; Bell KJL; Morton RL; Dieng M
Appl Health Econ Health Policy; 2023 Jan; 21(1):23-30. PubMed ID: 36195819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
